Catalyst Wire Dossier Catalyst Wire Dossier

MK3475

pembrolizumab · Merck & Co.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK3475, covering 2025-12-10 to 2025-12-10. Get the full timeline:

Most recent: Clinical Trial Update: Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial [Phase 2]

See pricing